

Investigation of Various Polymers for SLS 3D-Printing of Solid Oral Dosage Forms

Valerie R. Levine*, Evgenii Tikhomirov*, Julian Quodbach**, Nicole Di Gallo***, Thomas Kipping***, Jonas Lindh*



Purpose

- Selective laser sintering (SLS) is promising for printing oral dosage forms.
- Print ranges for commonly used pharmaceutical polymers not yet established for additive manufactured medications.
- Evaluate dedicated polymers for pharmaceutical applications.

Objectives

- Determination of optimal print conditions for various pharmaceutical-grade polymers (PVA 4-88 (Parateck® MXP), PVP-VA¹ (Kollidon VA64®), PVP-VA² (Plasdone™ S-630)).
- Usage conditions of dedicated PVA based polymers P1 (PVA3-82) and P2 (PVA5-74) in SLS printing and impact of hydrolysis degree on printing performance.

Methods

Materials and composition


- 10% API (indomethacin)
- 88.5% polymer (PVA, PVP-VA¹, PVP-VA², P1, and P2)
- 0.5% excipient (silicon dioxide colloidal)
- 1% colorant (silica-based effect pigment)

SLS of dosage forms

- 36 tablet batches created with the same conditions:

Layer Height (µm)	Perimeter Offset (µm)	Hatching Space (µm)	Hatching Offset (µm)	Number of Perimeters
125	50	50	150	3

- Prints done with three temperatures and three laser scan speeds: 75 °C, 100 °C, & 125 °C and 200 mm/s, 300 mm/s, and 400 mm/s, respectively.
 - For some materials, 125 °C was too high, so 112.5 °C was used
 - Tablets designed using Fusion360 modelling software:



- Printing occurs in layer-by-layer fashion in print bed (tablets fully submerged in powder post-printing, collected via sieving, and dedusted).
- 2.3 W diode (λ=455 nm) laser used.

Characterization


- XRD, DSC, friability, mass and size analysis, HPLC, dissolution.

Results

PVA-based tablets



PVP-VA¹-based tablets



PVP-VA²-based tablets



- Evidence of amorphous nature in all of the best print condition samples for each polymer.
- Trends of lower temperature and high laser scan speeds showed more evidence of crystallinity of the API.


	Number of Outliers for each configuration											
	75 °C, 200 mm/s	75 °C, 300 mm/s	75 °C, 400 mm/s	100 °C, 200 mm/s	100 °C, 300 mm/s	100 °C, 400 mm/s	112.5 °C, 200 mm/s	112.5 °C, 300 mm/s	112.5 °C, 400 mm/s	125 °C, 200 mm/s	125 °C, 300 mm/s	125 °C, 400 mm/s
PVA 3-82	-	-	-	2	4	18	-	-	-	1	2	1
PVA 5-74	1	-	-	0	3	-	-	-	-	0	1	0
PVP-VA ¹	13	-	-	0	9	13	5	3	7	-	-	-
PVP-VA ²	-	-	-	4	9	12	2	4	10	-	-	-
PVA 4-88	4	19	-	1	4	1	-	-	-	2	5	7

Table 1. Number of outliers for each printed batch, with less outliers being the ideal case.

P1-based tablets



P2-based tablets



- Printable tablets for each of the polymers tested with the best print by characterization and visual standard indicated via a red box.
- Tablets exhibit higher level of sintering at lower laser scan speeds and higher temperatures (within an appropriate temperature window).
- Mass deviation for the tablets with the best print parameters fell within Ph. Eur. 2.9.5-Uniformity of Mass of Single-Dose Preparation standards for traditional tablets.
- Number of outliers for tablets with the best print parameters did not always meet Pharmacopeia requirements (<2 outliers), but all viable samples were measured (standards require just 20 at random).
- Friability, while not fully meeting Ph. Eur. criteria for traditional tablets, performed well in some cases, especially for PVA-based tablets.

	Friability comparison of each identified configuration											
	P1 75 °C, 200 mm/s	P1 100 °C, 200 mm/s	P1 125 °C, 200 mm/s	P2 75 °C, 200 mm/s	P2 100 °C, 200 mm/s	P2 125 °C, 200 mm/s	PVP-VA ¹ 75 °C, 200 mm/s	PVP-VA ¹ 100 °C, 200 mm/s	PVP-VA ¹ 112.5 °C, 200 mm/s	PVP-VA ² 100 °C, 200 mm/s	PVP-VA ² 112.5 °C, 200 mm/s	PVA 4-88 125 °C, 200 mm/s
P1	-	-	-	12.0	51.9	-	-	-	-	2.3	9.3	22.9
P2	-	-	-	11.0	-	-	-	-	-	4.5	9.5	15.9
PVP-VA ¹	-	-	-	7.8	34.9	-	4.1	-	-	-	-	-
PVP-VA ²	-	-	-	7.0	-	-	4.5	22.6	-	-	-	-
PVA	11.2	-	-	4.3	20.2	-	-	-	-	2.0	9.1	-

Table 2. Friability for each printed batch, with lower friability being the ideal case.

Conclusions

- Higher temperatures within the print window for the polymers and lower laser scan speeds within the range tested generally led to superior samples.
- PVA based polymers were able to perform within a broad processing window (75–125 °C), whereas PVP-based polymers tested show an optimal upper limit of 112.5 °C.
- Best friability results were obtained using PVA grades.
- Most robust samples per batch tended to meet or come close to meeting current Pharmacopeia standards for traditional oral dosage forms.

Funding

The study was funded by MilliporeSigma.

References

1. Fina Fabrizio, Alvaro Goyanes, Simon Gaisford, and Abdul W. Basit. "Selective Laser Sintering (SLS) 3D Printing of Medicines." International Journal of Pharmaceutics 529, no. 1 (2017): 285-93. <https://doi.org/10.1016/j.ijpharm.2017.06.082>
2. Ivanovska Verica, Carin M.A. Rademaker, Liset van Dijk, and Aukje K. Mantel-Teeuwisse. "Pediatric Drug Formulations: A Review of Challenges and Progress." Pediatrics 134, no. 2 (August 1, 2014): 361-72. <https://doi.org/10.1542/peds.2013-3225>

* Division of Nanotechnology and Functional Materials, Department of Material Science and Engineering, Uppsala University.

** Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht.

*** MilliporeSigma

Contact details: Valerie.levine@angstrom.uu.se.

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the Vibrant M, SAFC, Parateck, Kollidon VA64 and Plasdone are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. Lit. No. MS_PS11632EN 11/2022

SAFC®

Pharma & Biopharma Raw Material Solutions